AP NEWS

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Insight, 2018 - ResearchAndMarkets.com

November 30, 2018

DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Juvenile Macular Degeneration (Stargardt Disease) development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Juvenile Macular Degeneration (Stargardt Disease) pipeline products by developmental stage, product type, molecule type, and administration route.

Scope

The report provides a snapshot of the pipeline development for the Juvenile Macular Degeneration (Stargardt Disease) The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Juvenile Macular Degeneration (Stargardt Disease) The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Juvenile Macular Degeneration (Stargardt Disease) The report also covers the dormant and discontinued pipeline projects related to the Juvenile Macular Degeneration (Stargardt Disease)

Reasons to Purchase

Establish comprehensive understanding of the pipeline activity across this Juvenile Macular Degeneration (Stargardt Disease) to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Juvenile Macular Degeneration (Stargardt Disease) therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Companies Featured

Astellas Pharma Acucela Inc. Alkeus Pharmaceuticals Inc. Katairo Astellas Pharma Inc. Copernicus Therapeutics Inc. Grupo Ferrer Internacional S.A. Iris Pharma

Key Topics Covered

1. Report Introduction

2. Juvenile Macular Degeneration (Stargardt Disease) Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease)

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5vggpw/juvenile_macular?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005354/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Optical Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 11:49 AM/DISC: 11/30/2018 11:49 AM

http://www.businesswire.com/news/home/20181130005354/en

AP RADIO
Update hourly